Vioxx Withdrawal Costs Merck Over $700 Mil. In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Impact of COX-2 inhibitor withdrawal reduces Merck’s quarterly earnings by over $550 mil. Merck reaffirms guidance for its major franchises, but Zocor sales are down for the quarter.